Association of tobacco smoke exposure with metabolic profile from childhood to early adulthood: the Special Turku Coronary Risk Factor Intervention Project

3D composite SERS substrate constructed by Au-Ag core-satellite NPs and polystyrene sphere for ultrasensitive ratiometric Raman detection of cotinine

To enhance the efficacy of Surface-enhanced Raman spectroscopy (SERS), noble metal nanoparticles (NMNPs) can be organized onto three-dimensional (3D) hierarchical nanostructures. This study involved constructing a 3D solid SERS substrate by layering Au-Ag core-satellite nanoparticle monolayer films (MF) on a polystyrene sphere (PS) array, termed Au-Ag core-satellite NPs-MF-PS. Optimizing the PS size was essential to maximize SERS substrate activity, with the 500 nm PS providing the best SERS enhancement factor of 1.03 × 107 a two-fold increase over Au-Ag core-satellite NPs MF alone. Additionally, cotinine detection was improved by using a ratio between the target molecules and internal Raman signals from the SERS substrate. Compared to conventional methods relying on the target molecule's Raman signal, this ratiometric SERS method expanded the detection range from 10-8 - 10-1 M to 10-9 - 10-1 M and reduced the detection limit from 3.67 × 10-9 M to 1.68 × 10-10 M. This approach represents a novel direction in creating ultra-sensitive SERS platforms with broad applications, suggesting that ratiometric SERS could further promote SERS technology advancements.

Blood pressure changes during smoking cessation in a randomized, double-blind, placebo-controlled trial of dulaglutide treatment

AIMS

Cigarette smoking cessation reduces cardiovascular risk via various mechanisms. Thereby, the role of blood pressure remains unclear, with studies reporting both decreased and increase blood pressure values after cessation, potentially influenced by weight change. We previously showed that the glucagon like peptide-1 analogue dulaglutide mitigates weight gain after smoking cessation. This secondary analysis investigates the effect of smoking cessation on blood pressure changes in dulaglutide- vs. placebo-treated individuals. We hypothesized a beneficial effect of smoking cessation on blood pressure, particularly in dulaglutide-treated participants.

METHODS AND RESULTS

This is a predefined secondary analysis of a randomized, double-blind, placebo-controlled trial. Participants (n = 255) underwent a 12-week smoking cessation programme including standard of care (behavioural counselling and varenicline) with weekly injections of dulaglutide 1.5 mg or placebo, followed by a follow-up of 52 weeks. The primary outcome was change in systolic blood pressure after 52 weeks in abstinent vs. smoking individuals. Further outcomes included blood pressure and body weight changes at Week 12 and 52 according to smoking status and treatment arms. A path analysis was performed to estimate direct and indirect effect of different variables on systolic blood pressure changes. Two hundred and eighteen out of 255 participants with complete blood pressure readings were included in the analyses. Across the entire study population, systolic blood pressure was stable over the period of 52 weeks after smoking cessation despite a weight gain of +3 kg (0, 5.4) at Week 52. Blood pressure reductions were seen in the subgroups of participants with minimal weight gain ≤3 kg [-4.6 mmHg (-9, 3)] and in individuals with hypertensive blood pressure values at baseline [-16 mmHg (-22, 2)]. Dulaglutide treatment reduced body weight and blood pressure initially, followed by a weight rebound and a blood pressure increase of +7.5 mmHg (-1, 15) at Week 52. The path analysis identified weight as an important factor influencing blood pressure during smoking cessation.

CONCLUSION

Our analysis suggests that smoking cessation may have a beneficial effect on blood pressure- especially in hypertensive individuals-, counteracting the expected blood pressure increase caused by post-cessation weight gain. However, it also underlines the importance of weight control after smoking cessation as a crucial factor in smoking cessation.

REGISTRATION

ClinicalTrials.gov: NCT03204396.